Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma

Hepatology

Volumn 37, Issue 6, 2003, Pages 1320-1328

  Cheng, Ann Lii ^a,b   Hsiung, Chao A ^b   Su, Ih Jen ^a   Chen, Pei Jer ^a,c   Chang, Ming Chih ^d   Tsao, Chao Jung ^e   Kao, Woei Yao ^f   Uen, Wu Ching ^g   Hsu, Chih Hung ^a   Tien, Hwei Fan ^a   Chao, Tsu Yi ^f   Chen, Li Tzong ^b   Whang Peng, Jacqueline ^b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d MACKAY MEMORIAL HOSPITAL   (Taiwan)

^e NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^f TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^g Shin Kong Memorial Hospital   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; ETOPOSIDE; GLUCOCORTICOID; HEPATITIS B SURFACE ANTIGEN; IFOSFAMIDE; METHOTREXATE; PREDNISOLONE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG CONTRAINDICATION; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INCIDENCE; LIVER HISTOLOGY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RISK FACTOR; RISK MANAGEMENT; STATISTICAL ANALYSIS; SURVIVAL RATE; VIRUS CARRIER; VIRUS REACTIVATION;

EID: 84984575715     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2003.50220     Document Type: Article

References (39)

1. Galbraith RM, Eddleston AL, Williams R, Zuckerman AJ. Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. Lancet 1975;2:528-530.
2. Wands JR, Chura CM, Roll FJ, Maddrey WC. Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology 1975;68:105-112.
3. Hoofnagle JH, Dusheiko GM, Schafer DF, Jones EA, Micetich KC, Young RC, Costa J. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 1982;96:447-449.
4. Thung SN, Gerber MA, Klion F, Gilbert H. Massive hepatic necrosis after chemotherapy withdrawal in a hepatitis B virus carrier. Arch Intern Med 1985;145:1313-1314.
5. Lau JYN, Lai CL, Lin HJ, Lok ASF, Liang RHS, Wu PC, Chan TK, Todd D. Fatal reactivation of chronic hepatitis B virus infection following withdrawal of chemotherapy in lymphoma patients. Q J Med 1989;73:911-917.
6. Pariente EA, Goudeau A, Dubois F, Degott C, Gluckman E, Devergie A, Brechot C, et al. Fulminant hepatitis due to reactivation of chronic hepatitis B virus infection after allogeneic bone marrow transplantation. Dig Dis Sci 1988;33:1185-1191.
7. Liang RHS, Lok ASF, Lai CL, Chan TK, Tood D, Chiu EKW. Hepatitis B infection in patients with lymphomas. Hematol Oncol 1990;8:261-270.
8. Lok ASF, Liang RHS, Chiu EKW, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy-report of a prospective study. Gastroenterology 1991;100:182-188.
9. Liaw YF. Hepatitis viruses under immunosuppressive agents. J Gastroenterol Hepatol 1998;13:14-20.
10. Alexopoulos CG, Vaslamatzis M, Hatzidimitriou G. Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumors. Br J Cancer 1999;81:69-74.
11. Markovic S, Drozina G, Vovk M, Fidler-Jenko M. Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy - a prospective study in 305 patients. Hepatogastroenterology 1999;46:2925-2930.
12. Liang R, Lau GKK, Kwong YL. Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. J Clin Oncol 1999;17:394-398.
13. Cheng AL. Steroid-free chemotherapy decreases the risk of hepatitis flare-up in hepatitis B virus carriers with non-Hodgkin's lymphoma. Blood 1996;87:1202.
14. Kumagai K, Takagi T, Nakamura S, Sawada U, Kura Y, Kodama F, Shimano S, et al. Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan. Ann Oncol 1997;8(Suppl 1):107-109.
15. Faggioli P, Paschale M, Tocci A, Luoni M, Fava S, De Paoli A, Tosi A, Cassi E. Acute hepatic toxicity during cyclic chemotherapy in non-Hodgkin's lymphoma. Haematologica 1997;82:38-42.
16. Perrillo RP. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001;120:1009-1022.
17. Sagnelli E, Manzillo G, Mario G, Pasquale G, Felaco FM, Filippini P, Izzo CM, et al. Serum levels of hepatitis B surface and core antigens during immunosuppressive treatment of HBsAg-positive chronic active hepatitis. Lancet 1980;2:395-397.
18. Scullard GH, Smith CI, Merigan TC, Roinson WS, Gregory PB. Effects of immunosuppressive therapy on viral markers in chronic active hepatitis B. Gastroenterology 1981;81:987-991.
19. Lam KC, Ching LL, Ng RP, Trepo C, Wu PC. Deleterious effect of predinosolone in HBsAg-Positive chronic active hepatitis. N Engl J Med 1981;304:380-386.
20. Hoofnagle JH, Davis GL, Pappas SC, Hanson RG, Peters M, Avigan MI, Waggoner JG, et al. A short course of prednisolone in chronic type B hepatitis. Ann Intern Med 1986;104:12-17.
21. Lee SD, Tong MJ, Wu JC, Lin HC, Tsai YT, Lo KJ. A randomized double-blind placebo-controlled trial of prednisolone therapy in HBeAg and HBV DNA positive Chinese patients with chronic active hepatitis B. J Hepatol 1991;12:146-150.
22. Hanson RG, Peters MG, Hoofnagle JH. Effects of immunosuppressive therapy with prednisolone on B and T lymphocyte function in patients with chronic type B hepatitis. HEPATOLOGY 1986;6:173-179.
23. Czaja AJ, Wolf AM, Baggenstoss AH. Laboratory assessment of severe chronic active liver disease during and after corticosteroid therapy: correlation of serum transaminase and gamma globulin levels with histologic features. Gastroenterology 1981;80:687-692.
24. Tur-Kaspa R, Burk RD, Shaul Y, Shafrits DA. Hepatitis B virus DNA contains a glucocorticoid responsive element. Proc Natl Acad Sci U S A 1986;83:1627-1631.
25. Chou CK, Wang LH, Lin HM, Chi CW. Glucocorticoid stimulates hepatitis B viral gene expression in cultured human hepatoma cells. HEPATOLOGY 1992;16:13-18.
26. Ohtsu T, Sai T, Oka M, Sugai Y, Tobinai K. Activation of hepatitis B virus infection by chemotherapy containing glucocorticoid in hepatitis B virus carriers with hematologic malignancies. Jpn J Clin Oncol 1991;21:360-365.
27. Sparano JA, Wiernik PH, Leaf A, Dutcher JP. Infusional cyclophosphamide, doxorubicin, and etoposide in relapsed and resistant non-Hodgkin's lymphoma: evidence for a schedule-dependent effect favoring infusional administration. J Clin Oncol 1993;11:1071-1079.
28. Cabanillas F. Non-Hodgkin's lymphomas: a review of the M.D. Anderson experience. Semin Oncol 1993;19:11-13.
29. Herbrecht R, Damonte JC, Dufoure P, Maloisel F, Liuk L, Ortiz S, Bergerat JP, et al. Etoposide, ifosfamide and methotrexate combination chemotherapy for aggressive non-Hodgkin's lymphoma after failure of the NLH 84 regimen. Semin Oncol 1992;197:7-10.
30. Berd D, Cornog J, Decont RC, Levitt M, Bertino JR. Long-term remission in diffuse histiocytic lymphoma treated with combination sequential chemotherapy. Cancer 1975;35:1050.
31. Remick SC, McSharry JJ, Wolf BC, Blanchard CG, Eastman AY, Wagher H, Portuese E, et al. Novel oral combination chemotherapy in the treatment of intermediate-grade and high grade AIDS-related non-Hodgkin's lymphoma. J Clin Oncol 1993;11:1691-1702.
32. Davis GL, Hoofnagle JH, Waggoner JG. Spontaneous reactivation of chronic hepatitis B virus infection. Gastroenterology 1984;86:230-235.
33. Sagnelli E, Manzio G, Maio G, Pasquale G, Felaco FM, Filippini P, Izzo CM, et al. Serum levels of hepatitis B surface and core antigens during immunosuppressive treatment of HBsAg-positive chronic active hepatitis. Lancet 1980;2:395-397.
34. Nair PV, Tong MJ, Stevenson D, Roskamp D, Boone C. Effects of short-term, high-dose prednisone treatment of patients with HBsAg-positive chronic active hepatitis. Liver 1985;5:8-12.
35. Perrillo RP, Campbell CR, Sanders GE, Regenstein FG, Bodicky CJ. Spontaneous clearance and reactivation of chronic hepatitis B virus infection among male homosexuals with chronic type B hepatitis. Ann Intern Med 1984;100:43-46.
36. Hoofnagle JH, Seeff LB. Natural history of chronic type B hepatitis. Prog Liver Dis 1982;7:469-479.
37. Rossi G, Pelizzari A, Motta M, Puoti M. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol. 2001;115:58-62.
38. Liao CA, Lee CM, Wu HC, Wang MC, Lu SN, Eng HL. Lamivudine for the treatment of hepatitis B virus reactivation following chemotherapy for non-Hodgkin's lymphoma. Br J Haematol 2002;116:166-169.
39. Marcello P, Fedele DM, Giovanni DGR, Alessandro S, Bruno P, Marco P, Atistide M, et al. Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus-infected patients treated for non-Hodgkin lymphoma. Blood 2002;99:724-725.